{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-036488","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.066847+00:00","generated_at":"2026-05-16T16:09:08.219085+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Moleculin Biotech announces 1-for-25 reverse stock split effective Dec 1, 2025","bullets":["Reverse stock split at 1:25 ratio effective 12:01 a.m. ET on December 1, 2025.","Outstanding shares reduced from ~51.6M to ~2.07M; authorized shares remain at 500M.","Series E and F warrants have potential exercise price adjustments based on VWAP.","No fractional shares issued; cash paid in lieu of fractional interests.","Ticker MBRX unchanged; new CUSIP number 60855D408."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-036488","json":"https://secwatch.observer/filing/0001437749-25-036488.json","markdown":"https://secwatch.observer/filing/0001437749-25-036488.md","text":"https://secwatch.observer/filing/0001437749-25-036488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925036488/0001437749-25-036488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925036488/mbrx20251124_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:09:08.219085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"629ede47f9aa6f079a201fdd529a4a4d480b3d56","claim":"Moleculin Biotech, Inc.: Approved amendment to certificate of incorporation to effect a 1-for-25 reverse stock split of common stock, effective December 1, 2025 (effective 2025-12-01).","evidence_excerpt":"At the Moleculin Biotech, Inc. (the “Company”) annual meeting of stockholders completed on August 18, 2025, the stockholders of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30, with such ratio to be determined in the discretion of the Company’s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion prior to the one-year anniversary of the annual meeting.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925036488/0001437749-25-036488-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-12-01"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}